Version 3.2.0 of the TMF Reference Model Launched
The TMF Reference Model Steering Committee announced that version 3.2.0 of the Trial Master File Reference Model is now available to download free of charge. This latest release incorporates updates developed in response to 25 requests from industry received through June 2020. As a result, Version 3.2.0 of the Reference Model reflects updated regulatory guidance and current industry best practices.
“This latest version of the TMF Reference Model builds on the hard work and incredible collaboration of so many people in our industry to standardize and simplify TMF management processes,” said Karen Roy, Chair of the TMF Reference Model Steering Committee. “In the 10 years since version 1.0 of the TMF Reference Model was launched, we have seen it embraced by organizations worldwide as a critical component supporting Trial Master File compliance and inspection-readiness. We fully expect version 3.2.0 to be a valuable contribution to this ongoing effort.”
To learn more, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
